

Peter Krajci

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1557401/publications.pdf>

Version: 2024-02-01

11
papers

358
citations

1307594

7
h-index

1281871

11
g-index

11
all docs

11
docs citations

11
times ranked

510
citing authors

#	ARTICLE	IF	CITATIONS
1	Concentrations of psychoactive substances in blood samples from non-fatal and fatal opioid overdoses. <i>British Journal of Clinical Pharmacology</i> , 2022, , .	2.4	4
2	Adapting treatment length to opioid-dependent individuals'™ needs and preferences: a 2-year follow-up to a 1-year study of extended-release naltrexone. <i>Addiction</i> , 2021, 116, 2084.	3.3	5
3	Availability of Extended-Release Naltrexone May Increase the Number of Opioid-Dependent Individuals in Treatment: Extension of a Randomized Clinical Trial. <i>European Addiction Research</i> , 2019, 25, 303-309.	2.4	7
4	Anxiety, Depression, and Insomnia Among Adults With Opioid Dependence Treated With Extended-Release Naltrexone vs Buprenorphine-Naloxone. <i>JAMA Psychiatry</i> , 2019, 76, 127.	11.0	44
5	No increased pain among opioid-dependent individuals treated with extended-release naltrexone or buprenorphine-naloxone: A 3-month randomized study and 9-month open-treatment follow-up study. <i>American Journal on Addictions</i> , 2019, 28, 77-85.	1.4	16
6	The LASSO Program in Oslo: Harm Reduction Using Buprenorphine-Naloxone (Suboxone®) in a Low Threshold Setting. <i>European Addiction Research</i> , 2018, 24, 286-292.	2.4	8
7	Effectiveness, safety and feasibility of extended-release naltrexone for opioid dependence: a 9-month follow-up to a 3-month randomized trial. <i>Addiction</i> , 2018, 113, 1840-1849.	3.3	20
8	Effectiveness of Injectable Extended-Release Naltrexone vs Daily Buprenorphine-Naloxone for Opioid Dependence. <i>JAMA Psychiatry</i> , 2017, 74, 1197.	11.0	200
9	Addressing misuse and diversion of opioid substitution medication: guidance based on systematic evidence review and real-world experience. <i>Journal of Public Health</i> , 2016, 38, e368-e374.	1.8	28
10	Buprenorphine dosing choices in specific populations: review of expert opinion. <i>Expert Opinion on Pharmacotherapy</i> , 2016, 17, 1727-1731.	1.8	13
11	Effects of Hemodialysis on Methadone Pharmacokinetics and QTc. <i>Clinical Therapeutics</i> , 2015, 37, 1594-1599.	2.5	13